Overcoming Cell Death Resistance In Cutaneous T Cell Lymphoma (Ctcl) By Combined Bcl-2 And Nf Kappa B Inhibition

Introduction and objectives: The lack of curative therapies and high relapse rates in CTCL make novel therapeutic approaches with higher efficacy rates and milder side effects necessary. To this end, combination therapies targeting different pathways are attractive for two reasons: they prevent development of therapy resistance and promise lower adverse event rates, as the single agent doses can be reduced. Inhibition of the anti-apoptotic protein Bcl-2 alone and in combination with NFκB blockade represents a promising therapeutic approach in CTCL, as it directly targets cell death resistance, a major factor in impairing therapeutic success in CTCL.